ActTrader voted as the ‘The Best Multi-Asset Platform’ at The Forex Expo, Dubai 2021
2.11.2021 12:56:00 EET | Business Wire | Press release
ActTrader, now a Finvasia Group Company, won this year’s best Multi-Asset Platform award at largest trading event in the MENA region - The Forex Expo, Dubai 2021. The award recognises businesses that push the boundaries of innovation in the Fintech space.
ActTrader provides customised solutions and dedicated technical infrastructure to some of the biggest forex brokers, hedge funds, ECN venues, multi-asset exchanges and financial institutions. They offer adaptive trading technology that works seamlessly through a single feature-rich application, eliminating the need of integrating with third-party applications.
When contacted, Sarvjeet Singh, co-founder Finvasia said he feels humbled to have achieved this milestone within the first year of their acquisition of ActTrader. "We envisage to build innovative technology solutions that meet the evolving needs of current and future needs of financial institutions," he further added.
The Fore Expo is one of the biggest trading event that hosts prestigious brokers, technology providers, financial institutions, banks, retail traders and media houses from the financial services industry. With more than 7000 in attendance, it is a place for people from the finance industry to coming together in one place.
"ActTrader has been making a buzz ever since its inception in 2000. It has helped thousands of multi-asset brokers and financial institutions globally to revolutionise their trading operations, hedge their risk, and yield profits with its tailor-made solutions." - Ilya Sorokin, Founder & CEO, ActTrader.
About ActTrader
ActTrader is a leading provider of multi-asset trading technologies with award-winning products including the state-of-the-art trading platform, order execution engine, CRM solutions, Auto Trading Algorithms, White Label Solutions, STP Liquidity through FIX API, Multi-platform bridge, AI-based social trading, crypto exchange, and other value-added services.
To expand the company’s B2B offerings, ActTrader joined forces with Finvasia Group- a multinational organisation that owns various brands in the financial services, healthcare, real estate, blockchain, and technology sectors.
Know more: https://acttrader.com/
About FINVASIA Group
FINVASIA is a multi-disciplinary, multinational organisation registered with regulatory bodies across the world, via its subsidiaries and sister concerns, in various capacities including SEC, USA (152771), CYSEC (367/18), FCA (850138), BaFin (157125), ACPR (85051), CONSOB (5151), CNVM (4892), Finanstilsynet (FT00118545) and more.
In India, Finvasia is registered with the Reserve Bank of India as an NBFC, NSE as a Professional Clearing member (M51912), BSE (4043), MCX (55135), and NCDEX as Trading Member (01259), AMFI (103331) and CDSL as Depository Participant (12084300).
Know more: https://finvasia.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211102005647/en/
Contact information
Media Contact
Ms. Sandeep Samra
media@stackflow.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bureau Veritas: A Steady Organic Revenue Growth in the First Quarter 202622.4.2026 08:30:00 EEST | Press release
Bureau Veritas (BOURSE:BVI): Q1 2026 Key figures1 › Revenue of EUR 1,547.0 million, up 4.5% organically, and down 0.8% year-on-year › Strong organic growth from Marine & Offshore at +11.2% and Buildings & Infrastructure at +7.3% with moderate growth for Consumer Products Services at +4.3%, Certification at +2.3%, Agri-Food & Commodities at +2.1%, and Industry at +0.7%, › Stable scope effect of (0.1)%, from bolt-on acquisitions (+1.8% contribution), net of disposals (-1.9%), › Negative currency impact of 5.2%, resulting from the euro’s appreciation against most currencies. Q1 2026 Highlights › Maintained steady performance across most regions, in an environment marked by disruptions related to the conflict in the Middle East; growth in the Industry business impacted by the delays of Opex-related services mainly in the Middle East, › Continued progress in execution of the Group’s LEAP | 28 strategy, pivoting its portfolio towards higher‑growth and higher‑margin activities. Four acquisiti
Bureau Veritas: A Steady Organic Revenue Growth in the First Quarter 202622.4.2026 08:30:00 EEST | Press release
Bureau Veritas (BOURSE:BVI): Q1 2026 Key figures1 › Revenue of EUR 1,547.0 million, up 4.5% organically, and down 0.8% year-on-year › Strong organic growth from Marine & Offshore at +11.2% and Buildings & Infrastructure at +7.3% with moderate growth for Consumer Products Services at +4.3%, Certification at +2.3%, Agri-Food & Commodities at +2.1%, and Industry at +0.7%, › Stable scope effect of (0.1)%, from bolt-on acquisitions (+1.8% contribution), net of disposals (-1.9%), › Negative currency impact of 5.2%, resulting from the euro’s appreciation against most currencies. Q1 2026 Highlights › Maintained steady performance across most regions, in an environment marked by disruptions related to the conflict in the Middle East; growth in the Industry business impacted by the delays of Opex-related services mainly in the Middle East, › Continued progress in execution of the Group’s LEAP | 28 strategy, pivoting its portfolio towards higher‑growth and higher‑margin activities. Four acquisiti
4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis22.4.2026 08:00:00 EEST | Press release
4Moving Biotech (4MB), a clinical-stage biotechnology company developing next-generation Disease-Modifying Osteoarthritis Drugs (DMOADs), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to 4P004 for the treatment of knee osteoarthritis in patients with synovitis who have not benefited from at least two prior pharmacological therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421591087/en/ 4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis This designation highlights both the serious burden of knee osteoarthritis and the persistent lack of disease-modifying treatment options. It also reflects the strong scientific rationale supporting the 4P004 development program, including its targeted intra-articular approach and the role of synovitis as a key marker of disease progression. 4P004 is a
4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis22.4.2026 08:00:00 EEST | Press release
4Moving Biotech (4MB), a clinical-stage biotechnology company developing next-generation Disease-Modifying Osteoarthritis Drugs (DMOADs), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to 4P004 for the treatment of knee osteoarthritis in patients with synovitis who have not benefited from at least two prior pharmacological therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421591087/en/ 4Moving Biotech Granted FDA Fast Track Designation to 4P004, Supporting an Accelerated Development Pathway in Knee Osteoarthritis This designation highlights both the serious burden of knee osteoarthritis and the persistent lack of disease-modifying treatment options. It also reflects the strong scientific rationale supporting the 4P004 development program, including its targeted intra-articular approach and the role of synovitis as a key marker of disease progression. 4P004 is a
LTM Wins Two Google Cloud Partner of the Year Awards for 202622.4.2026 05:30:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, announced today that it has received two Google Cloud Partner of the Year 2026 Awards. LTM is being recognized for its achievements in the Google Cloud ecosystem, helping joint customers to drive high-impact, scalable cloud transformations. LTM won the Google Cloud Partner of the Year Award in the Media & Entertainment category by modernizing a global media company's complex data estate with BigQuery. The transformation improved speed, lowered costs, and provided a scalable foundation, enabling real-time analytics and AI-ready pipelines. This approach offers a repeatable model for data modernization in Media and Entertainment industry. Additionally, LTM was honoured with another Google Cloud Partner of the Year Award for Infrastructure Modernization in North America and the transformation of the ERP landscape for a global leader in healthcare services. This resulted in faster time to market, modern scalable ecosys
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom